Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Prepaid Assets (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Prepaid Assets for 12 consecutive years, with $3.1 million as the latest value for Q1 2026.

  • For Q1 2026, Prepaid Assets rose 7.39% year-over-year to $3.1 million; the TTM value through Mar 2026 reached $3.1 million, up 7.39%, while the annual FY2025 figure was $3.0 million, 3.88% down from the prior year.
  • Prepaid Assets hit $3.1 million in Q1 2026 for Cartesian Therapeutics, up from $3.0 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $6.5 million in Q2 2022 and bottomed at $2.0 million in Q2 2024.
  • Average Prepaid Assets over 5 years is $3.9 million, with a median of $3.5 million recorded in 2023.
  • Year-over-year, Prepaid Assets crashed 52.0% in 2024 and then surged 32.93% in 2025.
  • Cartesian Therapeutics' Prepaid Assets stood at $3.8 million in 2022, then skyrocketed by 31.47% to $5.0 million in 2023, then crashed by 36.7% to $3.1 million in 2024, then decreased by 3.88% to $3.0 million in 2025, then increased by 3.81% to $3.1 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $3.1 million, $3.0 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.